SCHEMBL2035840

SCHEMBL2035840

N#CCC1CCC(N)CC1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28321266 1.00 KDM1A (0.31) KDM1A
SCHEMBL2035841 1.00 KDM1A (0.31) KDM1A
Hydrochloric Acid SCHEMBL1693693 0.97 KDM1A (0.30) KDM1A
Hydrochloric Acid SCHEMBL28979044 0.97 KDM1A (0.30) KDM1A
Hydrochloric Acid SCHEMBL1693691 0.97 KDM1A (0.30) KDM1A
SCHEMBL24197645 0.86 JAK2 (0.33)
SCHEMBL13907209 0.86 JAK2 (0.33)
SCHEMBL2162286 0.86 JAK2 (0.33)
SCHEMBL365047 0.86
SCHEMBL3908748 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125379-A1 PRODRUG OF JAK KINASE INHIBITOR E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2026-05-07 US disclosed
EP-4582425-A1 PRODRUG OF JAK KINASE INHIBITOR E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) 2025-07-09 EP disclosed
US-20250171458-A1 METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) 2025-05-29 US disclosed
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 US disclosed
EP-4509509-A1 METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND Hangzhou Highlightll Pharmaceutical Co., Ltd (CN) 2025-02-19 EP disclosed
US-20240228508-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2024-07-11 US disclosed
US-20240124412-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. 2024-04-18 US disclosed
WO-2024041586-A1 PRODRUG OF JAK KINASE INHIBITOR 启元生物(杭州)有限公司 2024-02-29 WO disclosed
CN-117355508-A Heterocyclic derivative and application thereof in medicine 西藏海思科制药有限公司 2024-01-05 CN disclosed
US-11851442-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE CORPORATION (US) 2023-12-26 US disclosed
EP-2397482-A1 Heteroaryl imidazolone derivatives as jak inhibitors Almirall, S.A. (ES) 2011-12-21 EP disclosed
EP-2397482-A1 Heteroaryl imidazolone derivatives as jak inhibitors Almirall, S.A. (ES) 2011-12-21 EP disclosed
EP-2365961-A2 PROCESS FOR PREPARING CYCLIC DIAMINES BASF SE (DE) 2011-09-21 EP disclosed
US-20110218323-A1 PROCESS FOR PREPARING CYCLIC DIAMINES BASF SE (DE) 2011-09-08 US disclosed
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2011-08-18 US disclosed
WO-2011086053-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2011-07-21 WO disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
WO-2010054988-A2 PROCESS FOR PREPARING CYCLIC DIAMINES BASF SE (DE) 2010-05-20 WO disclosed
US-20070082908-A1 Bicycle pyrazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228508-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 KDM1A 1997/4885
US-20250171458-A1 METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND BMP4, AZI2, CYP4B1 KDM1A 314/4885
US-20110218323-A1 PROCESS FOR PREPARING CYCLIC DIAMINES ODC1, PUF60, PARG KDM1A 221/4885
US-20240124412-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 KDM1A 242/4885
US-11851442-B2 Tricyclic fused thiophene derivatives as JAK inhibitors JAK1, JAK3, JAK2 KDM1A 1997/4885
US-20260125379-A1 PRODRUG OF JAK KINASE INHIBITOR JAK1, JAK2, JAK3 KDM1A 992/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C KDM1A 2985/4885
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CCNY, CCNA1, CCNA2 KDM1A 1324/4885
US-20070082908-A1 Bicycle pyrazole derivative DPP4, DPP7, DPP3 KDM1A 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.